All In Biotech

Drug Trial Radar · NCT04657198

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Last checked: Nov 20, 2026Latest source record: Jun 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

126

Actual

Start

Dec 9, 2020

Primary completion

Jun 3, 2021

Study completion Oct 25, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the parent study (NCT03814590). Based on safety and immunogenicity data from the parent study, RSVPreF3 OA investigational vaccine will be evaluated in further clinical research. Participants in selected groups will be invited to participate in this extension study. All participants who will be enrolled in the current extension study will receive the RSV investigational vaccine approximately 18 months after they received their respective dose-2 in the parent study.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccine (GSK3844766A)Biological

    RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Solicited Administration Site Adverse Events (AEs)Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
  2. Number of Participants With Any Solicited Systemic AEsTime frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
  3. Number of Participants With Any Unsolicited AEsTime frame: During the 30-day follow-up period post-vaccination (i.e., on the day of vaccination [Day 1] and 29 subsequent days)
  4. Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccinationTime frame: From Day 1 up to 30 days post-vaccination (Day 31)
  5. Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccinationTime frame: From Day 1 up to 30 days post-vaccination (Day 31)
  6. Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype ATime frame: At 30 days post-vaccination (Day 31)
  7. Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype BTime frame: At 30 days post-vaccination (Day 31)

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Elkridge, Maryland

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Wilrijk, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.